Published in Gene Therapy Weekly, May 13th, 2004
According to a study from the Peoples Republic of China, "the interaction of vascular endothelial cell growth factor (VEGF) and its receptors (Flt-1, Flk-1/KDR) regulates tumor angiogenesis. Therefore, blocking the binding of VEGF and the corresponding receptor has become critical for antitumor angiogenesis biological therapy. Our study extracted sFlk-1 fragment from embryo mouse liver using reverse transcription-polymerase chain reaction (RT-PCR), recombined it to retrovirus vector, and transfected it to tumor cell lines (S180 and B16) by the liposome mediated method, then we observed the biological...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.